From data to decisions: Enabling insights in global oncology development with integrated biomarker testing and CDx development

Precision oncology is reshaping cancer care, and biomarker testing is foundational to this transformation. In this Q&A, we explore how integrated biomarker testing and companion diagnostic (CDx) development strategies can accelerate therapeutic innovation, reduce risk and improve patient outcomes.

Q1: Why is biomarker testing so critical in oncology drug development?

Biomarker testing helps accelerate research and development, identify the right patients for a trial, improve patient stratification and reduce trial risk. A robust biomarker strategy can enhance therapy differentiation, streamline regulatory approval and improve ROI in a competitive landscape.

Q2: What are the operational challenges of implementing biomarker testing at scale?

Biomarker testing introduces complexity, especially in complex diseases such as cancers, where multiple biomarkers must be assessed from limited samples. These tests generate vast, multi-modal datasets often produced across many sites, making data harmonization resource intensive. Standardized workflows and strategic planning are essential to navigate this complexity and mitigate potential risks such as trial delays and compromised insights.

Q3: How does Labcorp support complex clinical trials and decentralized models?

With highly regulated, company-owned and operated central laboratories across key regions around the world, Labcorp provides standardized testing services to support clinical development, including FDA-authorized, clinical trial ready precision oncology services. This model expands access to testing, minimizes delays and supports sustainability goals, delivering measurable operational and environmental ROI.

“In today’s oncology landscape, speed and precision are everything. Our integrated biomarker and CDx solutions are designed to reduce complexity, align stakeholders and accelerate time to market—without compromising scientific rigor.” —Alan Arnold, Labcorp

Q4: What is a companion diagnostic (CDx), and why is it important?

A CDx is a test developed alongside a therapy to identify patients most likely to benefit from that specific treatment. In oncology, CDx tests guide treatment decisions, improve trial precision and strengthen regulatory submissions. They are essential tools in personalized medicine, enabling clinicians to deliver targeted therapies with greater confidence.

“CDx development isn’t just about the science—it’s about execution. Our integrated model simplifies stakeholder engagement and supports synchronized diagnostic–therapeutic launches.” —Alan Arnold, Labcorp

Q5: What are the key challenges in CDx development and commercialization?

CDx development requires precise regulatory planning, operational execution and coordination across diagnostic and therapeutic teams. Sponsors may face challenges in stakeholder engagement, global compliance and scalability—especially in decentralized trials.

Q6: How does Labcorp help sponsors bring CDx solutions to market?

Labcorp’s CDx commercialization services are purpose-built for compliance and delivery. Within our global infrastructure, we employ dedicated study teams with hands-on expertise in diagnostic development and global regulatory strategy. These teams work with partners to create a commercial strategy that includes market differentiation and reimbursement readiness. These integrated services simplify logistics, enhance data quality and accelerate CDx development, empowering sponsors to advance their programs with confidence.

Whether you're developing a new targeted therapy or expanding an existing indication, Labcorp’s biomarker and CDx solutions deliver faster insights, smarter trials and stronger commercialization outcomes.